The mammalian target of rapamycin (mTOR) is commonly activated in colon cancer. mTOR complex 1 (mTORC1) is a major downstream target of the PI3K/ATK pathway and activates protein synthesis by phosphorylating key regulators of messenger RNA translation and ribosome synthesis. Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors, and suppress proliferation and tumor angiogenesis and invasion. We now show that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenografts through the DR5, FADD and caspase-8 axis, and is strongly enhanced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 5-fluorouracil. The induction of DR5 by rapalogs is mediated by the ER stress regulator and transcription factor CHOP, but not the tumor suppressor p53, on rapid and sustained inhibition of 4E-BP1 phosphorylation, and attenuated by eIF4E expression. ATP-competitive mTOR/PI3K inhibitors also promote DR5 induction and FADD-dependent apoptosis in colon cancer cells. These results establish activation of ER stress and the death receptor pathway as a novel anticancer mechanism of mTOR inhibitors.
INTRODUCTION
Colorectal cancer (CRC) represents a major cancer burden worldwide, with over 1 million new cases and over 600 000 deaths annually. 1 CRC is the third leading cause of cancer death in the United States. 1 The cancer genome project has greatly advanced our understanding of cancer biology in the last decade, and identified frequent somatic mutations in oncogenic kinases. For example, deregulation of the PI3K/AKT signaling pathway is estimated in 60-70% of human colon cancers, leading to enhanced cell survival and proliferation. 2 Mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that regulates cell proliferation, motility, survival, protein synthesis and transcription. 3 mTORC1 is one of the two major mTOR complexes and a main downstream effector of PI3K/PTEN/AKT signaling in response to growth factors. mTORC1 phosphorylates downstream targets to increase protein synthesis, including S6K1 and its substrate ribosomal protein RPS6 and translation initiation inhibitor 4E-BP1. 3, 4 On phosphorylation, 4E-BP1 frees the eukaryotic translation initiation factor 4E (eIF4E) for capdependent mRNA translation. Hyperactivation of mTOR is an early and common event in colon cancer, [5] [6] [7] and generally caused by deregulation of upstream components. 3 Rapamycin is a natural product and non-ATP-competitive inhibitor of mTORC1. Rapamycin binds to cytosolic FK binding protein (FKBP12) with high affinity, and the resulting FKBP12/rapamycin complex then interacts with mTOR1 and inhibits its function by interfering with mTOR kinase activity or complex assembly. 3 Prolonged exposure to Rapamycin can inhibit mTORC2 in some cells. 3 Phosphorylation of 4E-BP1 in cancer cells has been reported to be much less susceptible to inhibition by Rapamycin than that of RPS6, while the underlying mechanisms are not well understood. 8 A number of Rapamycin analogs with improved pharmacologic properties, also referred as rapalogs, have been developed. Everolimus (RAD001), an orally available derivative of Rapamycin, and Temsirolimus (CCI-779) have been approved by the FDA (Food and Drug Administration) for the treatment of patients with refractory renal cell cancer, and in clinical trials for other solid tumors including colon cancer. 9,10 ATP-competitive mTOR or mTOR/PI3K dual inhibitors such as Torin 1 and NVP-BEZ235 have recently been developed. Antitumor activities of mTOR inhibitors are associated with suppression of tumor growth, angiogenesis and invasion. 3 Apoptosis is regulated by the intrinsic mitochondrial pathway 11 and extrinsic pathway. 12 The mitochondrial pathway is activated through the Bcl-2 family members Bax and Bak. 11, 13 The extrinsic pathway is activated on binding of pro-apoptotic ligands to the extended TNF family receptors, and negatively regulated by decoy receptors. 12 For example, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptor 4 (DR4), and DR5, which further recruit the adaptor Fas-associated protein with death domain (FADD) and caspase-8, leading to caspase-8 activation. 12 FADD is required for Fas-or TRAIL-induced apoptosis. 12 Induction of apoptosis is an important mechanism of many anticancer drugs. 14 Colon cancer cells deficient in BAX are highly resistant to anticancer agent-induced apoptosis, [15] [16] [17] [18] while the role of extrinsic pathway is much less understood. mTOR inhibitors, particularly rapalogs, induce cancer cell apoptosis in vivo, but not in culture at concentrations that inhibit p70S6K or RPS6 phosphorylation or cell proliferation. 3, 4 The significance of apoptosis induction in the anti-tumor activities of mTOR inhibitors remains undefined. In this study, we show that both rapalogs and ATP-competitive mTOR inhibitors can activate the extrinsic apoptotic pathway in CRC cells via the DR5/FADD/ caspase-8 axis on rapid inhibition of 4E-BP1 phosphorylation. Everolimus strongly synergizes with TRAIL and chemotherapy to induce FADD and DR5-dependent apoptosis. FADD-dependent apoptosis is required for the anti-tumor activities of Everolimus in xenografts. These results demonstrate activation of the extrinsic apoptotic pathway as an anti-tumor mechanism of mTOR inhibitors.
RESULTS
Rapalogs induce the activation of the death receptor pathway during apoptosis in colon cancer cells Everolimus and Temsirolimus induced classical apoptosis in HCT116 colon cancer cells by 48 h at high concentrations (18-20 μM) , which was unaffected in BAX knockout (BAX KO) or BAX/BAK double KO HCT116 cells (Figure 1a , Supplementary  Figures S1A and B ). The apoptosis was preceded by induction of DR5 as early as 8 h followed by cleavage of caspase-3, -8 and -9, and Bid within 24 h ( Figure 1b ). Reverse transcription-PCR (RT-PCR) analysis on a panel of extrinsic apoptotic regulators showed a strong induction of DR4, DR5 and TNFR1 (Figure 1c ). Significant apoptosis was induced in three other CRC lines including RKO, DLD1 and HT29 ( Figure 1d Figure S2 ). Unexpectedly, the treatment of rapalogs inhibited 4E-BP1 phosphorylation much more rapidly and profoundly compared with RPS6 phosphorylation Rapid dephosphorylation of 4E-BP1 by rapalogs leads to induction of ER stress and DR5 in CRC cells DR5 transcription is regulated by p53 following DNA damage 19, 20 or CHOP after ER stress. 21 We first ruled out p53, as DR5 and apoptosis was induced irrespective of p53 status (Figure 1 , Supplementary Figure S2 ), an p53 levels did not increase by either agent in p53 WT cells (Supplementary Figure S3 ). Interestingly, inhibition of 4E-BP1 phosphorylation and induction of CHOP were detected as early as 4 h, followed by DR5 in 12 h, only in cells treated with Everolimus at 20 μM (Figure 2a ). Overexpression of eIF4E attenuated CHOP, DR5 induction and caspase-3 cleavage ( Figure 2b ). In contrast, inhibition of 4E-BP1 phosphorylation, induction of CHOP or DR5 and apoptosis were absent in cells treated with Everolimus at 50 nM or 1 μM, despite more effective inhibition of RPS6 phosphorylation (Figure 2a ) and reversible growth suppression (data not shown). However, knockdown of raptor, rictor or mTOR by small-interfering RNA (siRNA) did not cause apoptosis or loss of p4E-BP1 ( Supplementary  Figures S3C and D) , supporting mTOR-independent 4E-BP1 phosphorylation in CRC cells. 22 Furthermore, Everolimus treatment led to CHOP recruitment to the DR5 promoter ( Figure 2c ), and CHOP knockdown by siRNA attenuated the induction of DR4 and DR5, as well as apoptosis and caspase activation by rapalogs (Figures 2d and e ). Interestingly, rapalogs-induced apoptosis was associated with strong activation of multiple ER stress markers besides CHOP induction, such as XBP-1 splicing, and upregulation of BIP, Ero1-Lα and IRE1α (Figure 2f ). These results demonstrate that CHOP is required for DR5 and apoptosis induction by rapalogs upon rapid inhibition of the 4E-BP1/eIF4 axis and activation of ER stress in HCT116 cells.
DR5 and caspase-8 are required for rapalog-induced apoptosis in CRC cells
We further determined if DR5 is required for apoptosis induced by Everolimus and Temsirolimus. Knockdown of DR5 by siRNA significantly suppressed apoptosis and cleavage of caspase-8 (Figure 5c ). Similar to rapalogs, Torin 1 at 50 nM or 1 μM completely inhibited RPS6 phosphorylation by 24 h, while induced no detectable apoptosis in HCT116 (Figure 5c ). These results strongly suggest that mTOR inhibitors activate ER stress and the extrinsic apoptotic pathway on selective inhibition of 4E-BP1 phosphorylation (Figure 5d ).
Everolimus sensitizes CRCs to other anticancer agents via the extrinsic pathway mTOR inhibitors activate apoptosis via p53-independent induction of DR5. We further hypothesized that they might sensitize CRCs to DR5 ligand TRAIL or chemotherapy that induces DR5 via p53 such as 5-FU ( Figure 5d ). As expected, TRAIL or 5-FU in combination with Everolimus strongly induced activation of caspase-8 and caspase-3 compared with single agent (Figure 6a (Figures 6b and c) . The combination of 5-FU and Everolimus enhanced DR5 induction (Figure 6d ). Therefore, Everolimus sensitizes CRC cells to killing via the activation of DR5 and the extrinsic pathway.
Apoptosis mediates the anti-tumor effect of Everolimus in a xenograft model
To establish a potential role of apoptosis in the anti-tumor activities of mTOR inhibitors in vivo, we treated mice bearing WT and FADD-KO HCT116 xenografts with 5 mg/kg Everolimus or the vehicle by oral gavage daily for 10 days. Everolimus treatment caused 80% reduction in tumor growth in the parental tumors, but o 30% in the FADD-KO tumors (Figure 7a ). Everolimus-treated tumors showed induction of DR5 associated with strong reduction in 4E-BP1 phosphorylation (Figure 7b ). Everolimus-treated tumors showed marked apoptosis in WT tumors as shown by TUNEL and active caspase-3 staining, which was significantly blocked in FADD-KO tumors (Figures 7c and d) . The inhibition of 4E-BP1 phosphorylation or angiogenesis was similar in WT and FADD-KO tumors in response to Everolimus (Figures 7e and f) . These data demonstrate an important role of the extrinsic apoptotic pathway and inhibition of 4E-BP1 phosphorylation in the anti-tumor activities of Everolimus in vivo.
DISCUSSION
The PI3K/PTEN/AKT/mTOR signaling pathway has a key role in cell proliferation, survival and transformation. 14 Recent studies suggest that activation of mTOR signaling is an early event in colon cancer, and its inhibition can lead to suppression of cell cycle progression, epithelial to mesenchymal transition, cell motility and metastasis. [5] [6] [7] Our current study establishes that high dose mTOR inhibitors activate CHOP-dependent induction of DR5 and apoptosis via the extrinsic pathway in colon cancer cells, on rapid and sustained inhibition of 4E-BP1 phosphorylation. To our knowledge, this is the first report to definitively show that apoptosis induction contributes significantly to the anti-tumor activities of mTOR inhibitors such as rapalogs in vitro and in vivo.
It is well established that, at sub micromolar concentrations, rapamycin or rapalogs do not inhibit phosphorylation of 4E-BP1 or cause apoptosis in cancer cells, despite effective inhibition of p70SK6 or RPS6 phosphorylation. These lower doses can promote formation of stress granules, reversible cell cycle arrest, and even apoptosis and chemo resistance. 23, 24 Interestingly, published work indicated that CCI-779 can reach high micromolars in the plasma of cancer patients. [25] [26] [27] The highest weekly dose of CCI-779 of 250 mg/m 2 (whole blood exposure of 15.5 μM) was associated with improved medium and overall survival, including a complete response, in heavily pretreated renal cancer patients. 25 The maximum drug concentrations in tumor tissues and underlying mechanisms are, however, not known. We believe our findings therefore provide a potentially novel and clinically relevant antitumor mechanism of rapalogs, particularly in extraordinary responders whose tumors contain activating mTOR mutations are recently reported. 28, 29 Emerging evidence supports targeting 4E-BP1 phosphorylation and translation in cancer. Our findings suggest that exposure to high doses of rapalogs causes a profound loss of 4E-BP1 phosphorylation and mTOR activity, both are likely required for the induction of ER stress, CHOP and DR5 and subsequent killing of cancer cells. This consistent with the competitive eIF4E/eIF4G inhibitor 4EGI-1 that induces apoptosis, 30, 31 mTOR-independent 4E-BP1 phosphorylation is associated with resistance to mTOR inhibitors 22, [32] [33] [34] and unresolved ER stress on persistent CHOP induction leading to DR5-mediated apoptosis. 35 However, the precise mechanism underlying inhibition of p4E-BP1, translation and ER stress warrants further investigation, and we could not rule out mTOR-independent effects. It is tempting to speculate that intermittent high dosing of rapalogs promotes more robust antitumor responses via induction of ER stress and apoptosis in mTOR addicted cancers particularly those with activating mTOR mutations. 28, 29 The major challenge in the clinical use of mTOR inhibitors is the lack of biomarkers or clear resistance mechanisms. 10 Induction of ER stress, death receptors and ligands, 4E-BP1 dephosphorylation and eIF4E/4E-BP ratio 36 might be potential biomarkers for selecting responders or monitoring responses. Rapalogs generally have a favorable safety profile and non-overlapping side effects with ATP-competitive inhibitors or DNA damaging agents. We showed that Rapalogs strongly synergize with TRAIL or 5-FU to induced cancer cell killing. Inhibitors of a variety of oncoproteins such as EGFR, MET, VEGFR, Raf, Hsp90 or Bcl-2/Bcl-xL, can activate mitochondria-dependent apoptosis in colon cancer cells. 17, 18, 37, 38 Therefore, their rational combination with rapalogs might offer hopes to patients with chemotherapy-refractory metastatic colon cancers 10 by activating both the intrinsic and extrinsic pathways.
Apoptosis is part of the normal turn-over of intestinal epithelium and has an important role in colon cancer biology, therapy and prevention, 39, 40 while its regulation can be different in normal and cancer cells and explored therapeutically. For example, FADD or casaspe-8 is required for normal development and homeostasis of gut epithelium by suppressing RIP-3 dependent necrosis in mice, 41 but dispensable for the survival of human CRC cells such as HCT116 and RKO. Recent studies suggest functional links of ER stress and mTOR, 42 and sensitization to ER stress on abnormal activation of mTOR in normal but not cancer cells. 43, 44 Rapamycin or rapalogs suppress intestinal carcinogenesis in mouse models with little or no long-term side effects. 45, 46 It will be important to determine if and how ER stress selectively kills cells with aberrant Wnt signaling, the driver of virtually all CRC. 2 In conclusion, our work demonstrates an essential role of the death receptor-mediated apoptosis on inhibition of 4E-BP1 phosphorylation in the anti-tumor activities of mTOR inhibitors 
MATERIALS AND METHODS

Western blotting
Western blotting was performed as previously described. 48, 49 Details on antibodies are found in the Supplementary Materials.
Real-time RT-PCR
Total RNA was isolated from cells using the Mini RNA Isolation II Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's protocol. One microgram of total RNA was used to generate complementary DNA using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Realtime PCR was carried out as described. 18 Details on primers are found in the Supplementary Materials (Supplementary Table S1 ).
Analysis of apoptosis and cell death
Apoptosis was analyzed by nuclear staining with Hoechst 33258 (Invitrogen), and Annexin V/propidium iodide (Invitrogen) followed by flow cytometry as described. 50 For colony formation assays, the same number of cells were treated and plated in 12-well plates at appropriate dilutions, and allowed to grow for 10-14 days before staining with crystal violet (Sigma, St. Louis, MO, USA). 16 Targeting FADD in HCT116 cells Gene targeting vectors were constructed by using the recombinant adenoassociated virus system as previously described. 51 HCT116 cells contain two copies of WT FADD. The FADD-KO cells with exon 2 deletion were generated following two rounds of gene targeting. Details for vector construction and identification KO clone isolation are found in the Supplementary Materials.
Transfection
The human FADD dominant negative and murine eIF4E expression constructs were kind gifts from Shiyong Sun (Emory University) and Nahum Sonenberg (McGill University), respectively. Transfection was performed using Lipofectamine 2000 according to the manufacturer's instructions. DR5, CHOP, Raptor, Rictor and mTOR siRNA duplexes were synthesized from Dharmacon (Lafayette, CO, USA). Details for transfection, drug selection and siRNA sequence are found in the Supplementary Materials.
Xenograft studies
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Female 5-6-week-old Nu/Nu mice (Charles River, Wilmington, MA, USA) were housed in a sterile environment with micro isolator cages and allowed access to water and chow ad libitum. Mice were injected subcutaneously in both flanks with 4 × 10 6 WT or FADD-KO HCT116 cells. After implantation, tumors were allowed to grow 7 days before the initiation of the treatment. Mice were randomized into two groups (n = 6 per group) receiving either vehicle or Everolimus (5 mg/kg per day) in saline on days 1-10 by oral gavage. Detailed methods on tumor measurements and analysis are provided in the Supplementary Materials. 38, 52, 53 Chromatin immunoprecipitation (ChIP) assay
ChIP was done using the Chromatin Immunoprecipitation Assay kit (Upstate Biotechnology, Lake Placid, NY, USA) according to the manufacturer's instructions. The precipitates were analyzed by PCR using primers 5′-AGGTTAGTTCCGGTCCCTTC-3′ (forward) and 5′-CAACTGCAAAT TCCACCACA-3′ (reverse).
Statistical analysis
Statistical analyses were carried out using GraphPad Prism IV software (La Jolla, CA, USA). P-values were calculated by the student's t-test and were considered significant if P o0.05. The mean ± 1s.d. were displayed in the figures.
